The approval of the generic version of smoking-cessation drug Chantix (varenicline) garnered a lot of attention as did the OKs of Besremi (ropeginterferon alfa-2b-njft), a treatment for polycythemia vera, and Trudhesa (dihydroergotamine mesylate), a nasal spray for acute treatment of migraines.
This is the first approval of generic version of Chantix, and it comes just weeks after a recall of the brand-name drug.
Besremi is the first interferon approved to treat a disease that causes the overproduction of red blood cells.
Vuity, developed by Allergan, is a once-daily eye drop to treat presbyopia.
The therapy, to be launched in October, is delivered quickly to the bloodstream by targeting the upper nasal space.
Genentech’s Susvimo is a refillable implant that delivers medication continuously for up to six months.